AE1 Retatrutide efficient 99%
TDS 16 Inquiries
81080-10-6
Pharmaceutical Grade
99.55%
shenzhen
AoXin
1mg/1vials,10vials/box
2026-10-15
GLP-1,Retatrutide,Selank,Tirzepatide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Acetamide, N-[4-hydroxy-3,5-bis(1-piperidinylmethyl)phenyl]-
Other Name:Acetamide, N-[4-hydroxy-3,5-bis(1-piperidinylmethyl)phenyl]-;N-(4-hydroxy-3,5-bis(piperidin-1-ylmethyl)phenyl)acetamide;ACE-083;N-[4-hydroxy-3,5-bis(1-piperidinylmethyl)phenyl]-
CAS No.:81080-10-6
Molecular Formula:C20H31N3O2
InChIKeys:InChIKey=AVPLCNNLKMYJHF-UHFFFAOYSA-N
Molecular Weight:345.48
Exact Mass:345.48
DSSTox ID:DTXSID00558571
Categories:
Characteristics-
Density:
1.176±0.06 g/cm3(Predicted)
Boiling Point:518.9±50.0 °C(Predicted)
PKA:9.91±0.50(Predicted)
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
GLP-1,Retatrutide,Selank,Tirzepatide
-
Location:
Room 1402, Unit 1, Building 1, Hongxing Mansion, Shanghang Road Sub-district, Hedong District, Tianjin
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
1 days
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History16 Inquiries
Country Product Purchase Quantity Date Posted
Russia
ace-083
10 G Aug 8, 2025
Bulgaria
ACE-083
1 KG Feb 8, 2025
United States
ACE-083 Acetamide, N-[4-hydroxy-3,5-bis(1-piperidinylmethyl)phenyl]-
3 G Jul 4, 2025
Netherlands
ACE-083
10 G Sep 15, 2026
Denmark
ACE-083
2 G Sep 10, 2026
United States
ACE-083
0.6 G Sep 5, 2026
Germany
ACE-083
10 G Mar 23, 2026
Germany
ACE-083, N-[4-hydroxy-3,5-bis(1-piperidinylmethyl)phenyl]- 3
5 G Mar 19, 2026
Armenia
ace-083
10 MG Aug 22, 2025
Japan
ACE 083
100 MT Jun 11, 2025
Denmark
ACE-083
2 G Sep 9, 2026
United States
ACE-083
10 G Mar 18, 2026
United Kingdom
Ace083 peptide
5 G Dec 23, 2025
United Arab Emirates
ACE 083
25 MG Dec 8, 2025
Japan
エース083
100000 MG Jun 11, 2025
Japan
エース083
10000 MG Jun 11, 2025 Post an enquiry for this product
More from this Seller
-
-
-
BT5 TB500 Peptide CAS No. 885340-08-9 Research Grade Raw Powder
Pharmaceutical Grade / 99.65%
$75/UNIT FOB
-
-
-
-
NJ1000 NAD+ 99% High quality, fast delivery, good service,Chinese warehouse
Pharmaceutical Grade / 99.55%
$89/UNIT FOB
-
-
-
-
2S50 SS-31 Peptide CAS 736992-21-5 99% Purity Research Peptide Lyophilized Powder Factory Supply with COA
Pharmaceutical Grade / 99.63%
$288/UNIT FOB
-
-
-
-
BPC High-end Peptide 5mg 10mg
Pharmaceutical Grade / 99.89%
$1.1/UNIT FOB
-
-
-
-
PIN20 Pinealon CAS 175175-23-2, >99% HPLC Purity, 20mg/Vial Lyophilized Powder
Pharmaceutical Grade / 99.55%
$116/UNIT FOB
-
-
-
-
KP10 KPV Peptide CAS 67727-97-3,>99% HPLC Purity, Lyophilized Powder
Pharmaceutical Grade / 99.55%
$58/UNIT FOB
-